Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients

New England Journal of Medicine

Volumn 324, Issue 10, 1991, Pages 641-648

  Golino, Paolo ^a   Piscione, Federico ^a   Cappelli Bigazzi, Maurizio ^a   Focaccio, Amelia ^a   Villari, Bruno ^a   Indolfi, Ciro ^a   Russolillo, Enrico ^a   Condorelli, Mario ^a   Chiariello, Massimo ^a   Willerson, James T ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETANSERIN; SEROTONIN;

ADULT; ANGIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; ENDOTHELIUM; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; VASOCONSTRICTION; VASODILATATION;

ADULT; BLOOD FLOW VELOCITY; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HUMAN; KETANSERIN; MIDDLE AGE; SEROTONIN; VASOCONSTRICTION; VASODILATION;

EID: 0026093083     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199103073241001     Document Type: Article

References (33)

1. Willerson J.T., Golino P., Eidt J., Campbell W.B., Buja L.M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80:198-205.
2. Hirsh P.D., Hillis L.D., Campbell W.B., Firth B.G., Willerson J.T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304:685-691
3. van den Berg E.K., Schmitz J.M., Benedict C.R., Malloy C.R., Willerson J.T., Dehmer G.J. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation 1989; 79:116-124
4. Rubanyl G.M., Frye R.L., Holmes D.R. Jr., Vanhoutte P.M. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J Am Coll Cardiol 1987; 9:1243-1249
5. Bush L.R., Campbell W.B., Buja L.M., Tilton G.D., Willerson J.T. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation 1984; 69:1161-1170
6. Ashton J.H., Schmitz J.M., Campbell W.B., et al. Inhibition of cyclic flow variations in stenosed canine coronary arteries by THROMBOXANE A2/prostaglandin H2 receptor antagonists. Circ Res 1986; 59:568-578
7. Schmitz J.M., Apprill P.G., Buja L.M., Willerson J.T., Campbell W.B. Vascular prostaglandin and thromboxane production in a canine model of myocardial ischemia. Circ Res 1985; 57:223-231
8. Ashton J.H., Ogletree M.L., Michel I.M., et al. Cooperative mediation by serotonin S2 and THROMBOXANE A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation 1987; 76:952-959
9. Ashton J.H., Benedict C.R., Fitzgerald C., et al. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986; 73:572-578
10. Golino P., Buja L.M., Ashton J.H., Kulkarin P., Taylor A., Willerson J.T. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation 1988; 78:701-711
11. Golino P., Ashton J.H., Buja L.M., et al. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo: THROMBOXANE A2 and serotonin are possible mediators. Circulation 1988; 79:154-166
12. Golino P., Buja L.M., Yao S.K., McNatt J., Willerson J.T. Failure of nitroglycerin and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: further evidence for THROMBOXANE A2 and serotonin as mediators of coronary artery vasoconstriction in vivo. J Am Coll Cardiol 1990; 15:718-726
13. Brum J.M., Sufan Q., Lane G., Bove A.A. Increased vasoconstrictor activity of proximal coronary arteries with endothelial damage in intact dogs. Circulation 1984; 70:1066-1073
14. Lamping K.G., Marcus M.L., Dole W.P. Removal of the endothelium potentiates canine large coronary artery constrictor responses to 5-hydroxytryptamine in vivo. Circ Res 1985; 57:46-54.
15. Chu A., Cobb F.R. Vasoactive effects of serotonin on proximal coronary arteries in awake dogs. Circ Res 1987; 61:Suppl II:II–81-II-87.
16. Cocks T.M., Angus J.A. Endothelium-dependent relaxation of coronary arteries by nonadrenaline and serotonin. Nature 1983; 305:627-630
17. Cappelli-Bigazzi M., Lamping K.G., Nuno D.W., Harrison D.G. Leukocyte and platelet-derived factors augment canine coronary constriction to serotonin. Am J Physiol 1990; 259:H1161-HI170.
18. Awouters F. The pharmacology of ketanserin, the first selective serotonin S2-antagonist. Drug Dev Res 1985; 6:263-300.
19. Spears J.R., Sandor T., Als A.V., et al. Computerized image analysis for quantitative measurement of vessel diameter from cineangiograms. Circulation 1983; 68:453-461
20. Wilson R.F., Laughlin D.E., Ackell P.H., et al. Transluminal, subselective measurement of coronary artery blood flow velocity and vasodilator reserve in man. Circulation 1985; 72:82-92.
21. Wilson R.F., White C.W. Intracoronary papaverine: an ideal coronary vasodilator for studies of the coronary circulation in conscious humans. Circulation 1986; 73:444-451
22. Sibley D.H., Millar H.D., Hartley C.J., Whitlow P.L. Subselective measurement of coronary blood flow velocity using a steerable Doppler catheter. J Am Coll Cardiol 1986; 8:1332-1340
23. Nabel E.G., Ganz P., Gordon J.B., Alexander R.W., Selwyn A.P. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressortest. Circulation 1988: 77:43-52.
24. Cohen M.L., Schenck K.W., Kurz K.D. 5–HT2-receptor antagonists: alpha1-vs. 5–HT2-receptor blocking properties in blood vessels. J Cardiovasc Pharmacol 1988; 11:Suppl 1:S25-S29.
25. Vanhoutte P.M., Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989; 80:1-9.
26. Benedict C.R., Mathew B., Rex K.A., Cartwright J. Jr., Sordahl L.A. Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation. Circ Res 1986; 58:58-67.
27. Cohen R.A., Shepherd J.T., Vanhoutte P.M. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 1983; 221:273-274
28. Cohen. 5-Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries. Am J Physiol 1983; 245:H1077-H1080.
29. Houston D.S., Shepherd J.T., Vanhoutte P.M. Adenine nucleotides, serotonin, and endothelium-dependent relaxations to platelets. Am J Physiol 1985; 248:H389-H395.
30. VanNueten J.M., Janssen P.A., Van Beek J., Xhonneux R., Verbeuren T.J., Vanhoutte P.M. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5–HT2 serotonergic receptors. J Pharmacol Exp Ther 1981; 218:217-230
31. Brazenor R.M., Angus J.A. Action of serotonin antagonists on dog coronary artery. Eur J Pharmacol 1982; 81:569-576
32. Heistad D.D., Armstrong M.L., Marcus M.L., Piegors D.J., Mark A.L. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res 1984; 54:711-718
33. De Caterina R., Carpeggiani C., L#x0027;Abbate A. A double-blind, placebo controlled study of ketanserin in patients with Prinzmetal#x0027;s angina: evidence against a role for serotonin in the genesis of coronary vasospasm. Circulation 1984; 69:889-894